Enlivex Therapeutics Ltd. — FY 2022 Form 20-F
Period: Fiscal year ended December 31, 2022. The filing is an annual report, not a standalone Q4 report; it does not provide separate Q4 financial results. Amounts below are in U.S. dollars unless stated otherwise.
Business context
Enlivex is a clinical-stage biotechnology company developing Allocetra, an off-the-shelf cell therapy intended to restore macrophage homeostasis. Its primary programs are sepsis and solid tumors. The company reported no product revenue and has not commercialized any product.
Financial performance and position
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense, net | $18.693 million | $12.881 million |
| General and administrative expense | $7.104 million | $6.407 million |
| Operating loss | $25.797 million | $19.288 million |
| Net loss | $31.060 million | $14.468 million |
| Basic and diluted loss per share | $1.69 | $0.81 |
| Net cash used in operations | $23.953 million | $17.542 million |
Net loss widened 115% year over year. Operating expenses rose 34%, including a 45% increase in R&D, primarily from clinical and preclinical studies, personnel, materials and facility-related costs. The shift in other income/expense also weighed on results: FY 2022 included $1.983 million of losses on marketable securities and $4.101 million of foreign-exchange expense, versus net other income of $4.820 million in FY 2021. No meaningful margin comparison is available because the company had no revenue.
At year-end, cash and cash equivalents were $49.945 million and short-term deposits were $0.299 million; marketable securities were zero, compared with $62.924 million in 2021. Working capital was approximately $45.7 million. Total assets were $67.642 million, total liabilities $10.801 million and shareholders’ equity $56.841 million. The filing presents no conventional borrowing balance; lease liabilities totaled $4.847 million. Separately, the company disclosed a contingent obligation to the Israel Innovation Authority (IIA) of approximately $9.2 million, including interest.
Cash from investing activities was $62.524 million, largely reflecting proceeds from sales of marketable securities; this was not operating cash generation. Financing activities provided $0.150 million, versus $60.982 million in 2021, when the company raised equity and received warrant-exercise proceeds. Cash used for property and equipment was $8.122 million in 2022.
Material changes and developments
- R&D spending increased $5.812 million, driven mainly by clinical and preclinical work, additional staff and increased dose manufacturing.
- The company completed development of a frozen Allocetra formulation in Q1 2022, ahead of schedule. Its shelf life is expected to be multiple years, compared with 96 hours for the liquid formulation; the company expects improved logistics and scalability.
- In 2022, the Phase II sepsis trial protocol was amended to use frozen formulation for new patients and include additional infection sources. A further amendment was planned for Q2 2023 to include patients with higher SOFA scores and move from four cohorts to two.
- Two solid-tumor Phase I/II trials began in 2022: one combining Allocetra with chemotherapy for peritoneal metastases, and another evaluating monotherapy and combinations with anti-PD-1 therapy. The company reported positive DSMB recommendations to continue both trials.
- Construction of a cGMP manufacturing plant was completed in Q4 2022. As part of cost reductions, the planned move into the facility was deferred for approximately three years, and the company planned to offer the space and related services to potential tenants.
- The company deprioritized its COVID-19 program and redirected resources to sepsis and oncology. It said Phase IIb enrollment was insufficient for meaningful efficacy assessment; enrolled patients would continue to be followed for safety.
Outlook, risks and contingencies
Management estimated existing resources would support planned operations through Q4 2024. A company-wide cost-cutting plan may extend the runway into 2025, but the company expects to need substantial additional funding. It disclosed substantial doubt about its ability to continue activities beyond Q4 2024 without additional capital. A $100 million at-the-market facility was authorized in December 2022, but sales are optional and it is not committed financing; the company reported issuing 110,115 shares under it in Q1 2023.
Management expected sepsis top-line data in Q1 2024 and completion of enrollment and data readouts for the chemotherapy-combination solid-tumor study by Q2 2024. Enrollment in specified monotherapy and low-dose combination cohorts of the other solid-tumor study was expected to finish by the end of Q2 2023. These are forward-looking targets, not assured outcomes. The filing also describes a clinical collaboration with BeiGene to evaluate Allocetra with tislelizumab.
- Development and regulatory risk: Allocetra remains investigational; early or historical results may not predict later-trial results, regulatory approval or commercial success. The reported Phase Ib sepsis findings were compared with matched historical controls, not a concurrent randomized control group.
- Funding and dilution: recurring losses and operating cash use make additional financing necessary; equity issuance could dilute shareholders, while partnerships could require rights concessions.
- Manufacturing: cell-based production depends on controlled collection, handling and testing of blood-derived materials and compliance with cGMP. The new plant is not planned for company use for approximately three years.
- IIA obligations: grants carry royalties generally of 3%–5% on relevant sales until repayment, plus interest. Restrictions on transferring supported technology or manufacturing outside Israel may require approval and could increase amounts payable.
- Currency exposure: the company reported $25.763 million of net assets denominated in NIS; a 5% U.S. dollar/NIS move would change expenses by approximately $1.288 million. It had no currency hedges at year-end.
- Other risks: competition, clinical-trial delays, product safety, intellectual-property protection, reimbursement, reliance on third parties, and political or security developments in Israel were identified as material risks.
The independent auditor issued an unqualified opinion on the financial statements and internal control over financial reporting and reported no critical audit matters. Management also concluded disclosure controls and internal control over financial reporting were effective as of December 31, 2022.
Important facts for investors to verify
- Actual cash burn, subsequent financing and share issuance, and whether the stated runway assumptions remain achievable.
- Progress, enrollment, safety findings and timing of the Phase II sepsis readout and both solid-tumor trials.
- Whether frozen-formulation shelf-life, manufacturing consistency, cost and logistics claims are validated at clinical scale.
- Use of the completed manufacturing facility during its planned deferral, including any leasing income, costs or commitments.
- The status and potential financial impact of IIA royalties, transfer restrictions and the disclosed contingent obligation.
- Whether later filings clarify subsequent clinical results, regulatory interactions, financing needs or changes to management’s outlook.